Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 17, 2011. The report details a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 430,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,185.5 pence per share; lowest price paid was 1,170.0 pence per share.
- Treasury Holdings (Settled): 481,037,284 shares (8.48% of total issued share capital).
- Treasury Holdings (Including Unsettled): 482,762,284 shares (9.30% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,189,755,207 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 430,000 shares on February 17, 2011. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure of a specific corporate action.
Key Facts for Investor Verification
- Verify the total cost of the 430,000 shares purchased based on the reported price range (1,170.0 to 1,185.5 pence).
- Confirm the impact of the 9.30% treasury holding on total voting rights calculations.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.
- Review the remaining authorization for share buybacks under the May 2010 shareholder mandate.